UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Xilio Therapeutics Inc (XLO)

Xilio Therapeutics Inc (XLO)
0.7200 x 42 0.7700 x 5
Pre-market by (Cboe BZX)
0.7460 +0.0161 (+2.21%) 03/28/25 [NASDAQ]
0.7200 x 42 0.7700 x 5
Pre-market 0.7687 +0.0227 (+3.04%) 08:58 ET
Quote Overview for Mon, Mar 31st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7201
Day High
0.7201
Open 0.7201
Previous Close 0.7460 0.7460
Volume 4,932 4,932
Avg Vol 415,782 415,782
Stochastic %K 18.70% 18.70%
Weighted Alpha -64.56 -64.56
5-Day Change -0.0656 (-8.35%) -0.0656 (-8.35%)
52-Week Range 0.6300 - 1.7000 0.6300 - 1.7000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,623
  • Shares Outstanding, K 51,774
  • Annual Sales, $ 6,340 K
  • Annual Income, $ -58,240 K
  • EBIT $ -61 M
  • EBITDA $ -59 M
  • 60-Month Beta -0.38
  • Price/Sales 5.96
  • Price/Cash Flow N/A
  • Price/Book 1.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.25
  • Most Recent Earnings $-0.20 on 03/11/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.19
  • Number of Estimates 3
  • High Estimate 0.38
  • Low Estimate -0.19
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +132.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6900 +4.36%
on 03/28/25
Period Open: 0.9060
0.9799 -26.51%
on 03/03/25
-0.1859 (-20.52%)
since 02/28/25
3-Month
0.6300 +14.30%
on 02/04/25
Period Open: 0.9722
1.7000 -57.64%
on 02/12/25
-0.2521 (-25.93%)
since 12/27/24
52-Week
0.6300 +14.30%
on 02/04/25
Period Open: 1.0800
1.7000 -57.64%
on 02/12/25
-0.3599 (-33.32%)
since 03/28/24

Most Recent Stories

More News
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

XLO : 0.7201 (-3.47%)
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

XLO : 0.7201 (-3.47%)
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

XLO : 0.7201 (-3.47%)
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

XLO : 0.7201 (-3.47%)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XLO : 0.7201 (-3.47%)
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

/CNW/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25 in...

ONCY : 0.5900 (-1.67%)
AGEN : 1.5600 (-2.50%)
GH : 40.38 (-6.41%)
XLO : 0.7201 (-3.47%)
ONC.TO : 0.85 (-5.56%)
RNXT : 1.0000 (-1.96%)
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

XLO : 0.7201 (-3.47%)
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

XLO : 0.7201 (-3.47%)
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

XLO : 0.7201 (-3.47%)
Xilio Therapeutics Reports Preliminary Phase 1 Data for XTX301 Showing Improved Tolerability and Completes Private Placement with Gilead

Xilio Therapeutics reports promising Phase 1 data for XTX301 with improved tolerability and completed equity investment from Gilead.Quiver AI SummaryXilio Therapeutics, Inc. announced preliminary Phase...

XLO : 0.7201 (-3.47%)

Business Summary

Xilio Therapeutics Inc. is a biotechnology company which focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company's product candidate includes XTX101, XTX202, XTX301 and XTX401 which are in clinical stage. Xilio Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.8207
2nd Resistance Point 0.7833
1st Resistance Point 0.7647
Last Price 0.7201
1st Support Level 0.7087
2nd Support Level 0.6713
3rd Support Level 0.6527

See More

52-Week High 1.7000
Fibonacci 61.8% 1.2913
Fibonacci 50% 1.1650
Fibonacci 38.2% 1.0387
Last Price 0.7201
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies